Oragenics Files S-1/A Amendment
Ticker: OGEN · Form: S-1/A · Filed: Sep 3, 2024 · CIK: 1174940
Sentiment: neutral
Topics: sec-filing, registration-statement, amendment
Related Tickers: ORGN
TL;DR
ORGN S-1/A filed 9/3. Standard update, nothing major.
AI Summary
Oragenics, Inc. filed an S-1/A amendment on September 3, 2024, regarding its registration statement. The filing details its corporate information, including its Florida incorporation, IRS number 59-3410522, and principal executive offices located at 1990 Main Street, Suite 750, Sarasota, Florida. J. Michael Redmond is listed as President.
Why It Matters
This filing is an amendment to Oragenics' registration statement, indicating ongoing efforts to comply with SEC regulations for public offerings or reporting requirements.
Risk Assessment
Risk Level: low — This filing is a routine amendment to a registration statement and does not contain new material financial information or significant business changes.
Key Numbers
- 333-281618 — SEC File Number (Identifies the specific registration statement with the SEC.)
- 59-3410522 — IRS Number (The company's Employer Identification Number.)
Key Players & Entities
- ORAGENICS INC (company) — Registrant
- J. Michael Redmond (person) — President
- 1990 Main Street, Suite 750, Sarasota, Florida 34236 (location) — Principal Executive Offices
- 333-281618 (registration_number) — SEC File Number
- 59-3410522 (irs_number) — IRS Employer Identification No.
FAQ
What is the purpose of this S-1/A filing?
This is an amendment (Amendment No. 1) to the original S-1 registration statement filed by Oragenics, Inc., as indicated by the form type 'S-1/A'.
When was this amendment filed?
The filing was made on September 3, 2024.
Where is Oragenics, Inc. headquartered?
The company's principal executive offices are located at 1990 Main Street, Suite 750, Sarasota, Florida 34236.
Who is the President of Oragenics, Inc. mentioned in the filing?
J. Michael Redmond is listed as the President of Oragenics, Inc.
What is the company's state of incorporation?
Oragenics, Inc. is incorporated in Florida.
Filing Stats: 4,564 words · 18 min read · ~15 pages · Grade level 16.7 · Accepted 2024-09-03 16:06:54
Key Financial Figures
- $1.27 — at an assumed public offering price of $1.27 per share, the last reported sale price
- $0.001 — mmon Stock and has an exercise price of $0.001 per share. The assumed offering price p
- $350,000 — cement agent fee, will be approximately $350,000. We are also registering up 196,850 P
- $1,000,000 — acquisition, we paid Odyssey a total of $1,000,000 in cash, $500,000 of which was paid in
- $500,000 — Odyssey a total of $1,000,000 in cash, $500,000 of which was paid in October, 2023 and
- $6.9 billion — for concussion treatment was valued at $6.9 billion in 2020 and is forecast to reach $8.9 b
- $8.9 billion — illion in 2020 and is forecast to reach $8.9 billion by 2027, according to Grandview Researc
Filing Documents
- forms-1a.htm (S-1/A) — 763KB
- ex5-1.htm (EX-5.1) — 19KB
- ex23-1.htm (EX-23.1) — 5KB
- ex23-2.htm (EX-23.2) — 5KB
- ex107.htm (EX-FILING FEES) — 46KB
- forms-1_001.jpg (GRAPHIC) — 20KB
- forms-1_002.jpg (GRAPHIC) — 12KB
- ex5-1_001.jpg (GRAPHIC) — 21KB
- 0001493152-24-034815.txt ( ) — 1263KB
- ogen-20240903.xsd (EX-101.SCH) — 3KB
- ogen-20240903_def.xml (EX-101.DEF) — 29KB
- ogen-20240903_lab.xml (EX-101.LAB) — 36KB
- ogen-20240903_pre.xml (EX-101.PRE) — 26KB
- forms-1a_htm.xml (XML) — 4KB
USE OF PROCEEDS
USE OF PROCEEDS 20 DIVIDEND POLICY 20 CAPITALIZATION 20
DESCRIPTION OF CAPITAL STOCK
DESCRIPTION OF CAPITAL STOCK 23
DESCRIPTION OF SECURITIES WE ARE OFFERING
DESCRIPTION OF SECURITIES WE ARE OFFERING 30 PLAN OF DISTRIBUTION 32 EXPERTS 35 LEGAL MATTERS 35 INCORPORATION BY REFERENCE 35 WHERE YOU CAN FIND MORE INFORMATION 37 ABOUT THIS PROSPECTUS We incorporate by reference important information into this prospectus. You may obtain the information incorporated by reference without charge by following the instructions under "Where You Can Find More Information." You should carefully read this prospectus as well as additional information described under "Incorporation of Certain Information by Reference," before deciding to invest in our securities. You should rely only on the information contained in this prospectus. We have not, and the Placement Agent has not, authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectuses prepared by or on behalf of us or to which we have referred you, and we take no responsibility for any other information others may give you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the securities offered hereby, and only under circumstances and in jurisdictions where it is lawful to do so. We are not making an offer to sell these securities in any jurisdiction where an offer or sale is not permitted. The information contained in this prospectus or in any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of our securities. Our business, financial condition, results of operations and prospects may have changed since that date. The information incorporated by reference or provided in this prospectus contains statistical data and estimates, including those relating to market size and competitive position of the markets in which we participate, that we obtained from our own internal estimates an